Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a devastating neuromuscular disorder caused by mutations in the survival of motor neuron 1 (<i>SMN1</i>) gene, which leads to a reduced level in the SMN protein within cells. Patients with SMA suffer from a loss of alpha motor neurons in the spinal cord l...
Main Authors: | Charlotte A. René, Robin J. Parks |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-06-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/15/6/1764 |
Similar Items
-
Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study
by: Georg M. Stettner, et al.
Published: (2023-02-01) -
Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports
by: Tomoko Mizuno, et al.
Published: (2023-10-01) -
Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
by: Andrada Mirea, et al.
Published: (2021-11-01) -
Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy
by: Ramos-Platt L, et al.
Published: (2022-09-01) -
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)
by: Rebecca Dean, et al.
Published: (2021-01-01)